866-997-4948(US-Canada Toll Free)

Viral Inactivation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Sep 2017

Category :

Biotechnology

No. of Pages : 227 Pages

Global Viral Inactivation Market: Overview

Viral clearance study is one of the most important aspect for clinical trials, for manufacturing and commercialization of biopharmaceutical products derived from human and animal sources. Biologics products developed from human, plants and animal resources represents the higher levels of risk for viral contamination as these sources are known to carry number of human as well as other pathogenic viruses. Viral contamination of these biologics products used for treatment of variety of disease can have the several implications right from severe clinical complications to economic loss.

Viral clearance studies in large scale bio manufacturing process ensures the viral safety of biological products by screening the raw materials, testing the process intermediates and evaluates the capability and effectiveness of manufacturing process to achieve the desired level of viral safety of biologic products. Several methods have been developed and are currently practiced by the biopharmaceutical companies and other end users to ensure the viral safety of biologics products. The methods includes chemical method, radiation method and other methods such as pasteurization and dry & moist heat treatment.

Viral inactivation methods have broad applications in blood & blood components, vaccines production, cell & tissue culture products and other biologics products. These viral clearance method help maximize the production by establishing operational parameters at different stages without hampering product quality.

Global Viral Inactivation Market: Drivers

Rapid growth of biosimilars and biologics market in global biopharmaceutical industry, Regulatory compliances for viral inactivation of biologics products, and increasing number of new drugs approval are some of the key driving factors for the growth of global viral inactivation market during forecast period. In 2015, 51 drugs were approved out of which 45 drugs approved by Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) and 6 approved by Center for Biologics Evaluation and Research (CBER). Also In March 2015, the US FDA approved the first biosimilars product for marketing in the United States. Since then large number of biosimilars products have been filed for FDA clearance and many new applications are anticipated to be filed during forecast period.

It is estimated that more than US$ 100 Bn biologics products market will go off patent in next few years which will open the window for the biosimilars products market. This estimated growth in biosimilars market is projected to be key driving factor for global viral inactivation market. However the high cost of biologics and biosimilars products development and manufacturing and high cost of equipment for viral inactivation are likely to limit the growth of viral inactivation market during forecast period. Emergence of new viruses and development of vaccines against these viruses, development and adoption of newer viral inactivation methods and Growing application monoclonal antibodies and recombinant proteins for treatment of variety of diseases represents the new market opportunity for global viral inactivation market during forecast period.

Global Viral Inactivation Market: Segmentation

Global viral inactivation market is broadly segmented in four segments on the basis of methods used for viral inactivation, by application, by end user and by region. Based on methods, viral inactivation market has been segmented into chemical methods, radiation method, and other methods of viral inactivation. Out of these methods, chemical method of viral inactivation dominated the market.  Chemical method is further sub-segmented into solvent detergent method, use of alkylating agent method and pH concentration method. The Solvent detergent method is projected to account largest market share by the end of 2025.  

Chemical method is considered as the robust & efficient method for inactivation of variety of enveloped viruses. Also this method of viral inactivation is found to be economic, safer and delivers higher levels of purity of sample/ media. These advantages of chemical method have made the end user the first preference for viral inactivation. Radiation method for viral inactivation is projected to witness highest CAGR during forecast period owing to increased adoption of this method by most of blood center in developed countries.

By application, global viral inactivation market is segmented into blood and blood products, vaccines and cell & tissue culture products. Blood and blood products dominated the market due to high cost of viral inactivation per unit of blood and blood components, increasing demand for plasma and platelets for transfusion therapy globally. The end user of global viral inactivation market includes the pharmaceutical and biotechnology companies, blood banks & hospitals, contract research organizations and other end users.

Geographically, the global viral inactivation market is segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. These regions have been further segmented by countries, methods, applications and end-users. North America dominated the market and is anticipated to lose its market share to Asia Pacific region by the end of 2025.

Global Viral Inactivation Market: Competitive Landscape

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global viral inactivation market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major companies competing in the global viral inactivation market, and profiled in the report include Parker Hannifin Corporation, Merck & Co., Inc., Shandong Weigao Group Medical Polymer Company Limited, Sartorius AG, Cerus Corporation, Macopharma SA, Terumo BCT, Inc., Thermo Fisher Scientific Inc. and V.I.P.S. SA

Global Viral inactivation Market is segmented as given below:

Global Viral Inactivation Market, by Method

  • Chemical Method
  • Radiation Method
  • Other Methods

Global Viral Inactivation Market, by Application

  • Blood & Blood Products
  • Vaccines
  • Cell & Tissue Culture

Global Viral Inactivation Market, by End-user

  • Pharmaceutical & Biotechnology Companies
  • Blood Banks & Hospitals
  • Contract Research Organizations
  • Other

Global Viral Inactivation Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Content

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Viral Inactivation market 

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Viral Inactivation Method Introduction
4.1.2. Industry Evolution / Developments

Chapter 5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Trends
5.5. Viral Inactivation market  Analysis and Forecast, 2017 – 2025
5.5.1. Market Revenue Projections (US$ Mn), 2017-2025
5.6. Porter’s five forces analysis
5.7. Market Outlook

Chapter 6. Global Viral Inactivation market  Analysis and Forecasts, by Method
6.1. Key Findings 
6.2. Introduction 
6.3. Market size (US$ Mn) Forecast, by Method, 2017-2025
6.3.1. Chemical method
6.3.1.1. Solvent & Detergents
6.3.1.2. Alkylating Agents
6.3.1.3. pH Concentration
6.3.2. Radiation Method
6.3.3. Other Methods
6.4. Market Attractiveness Analysis, by Method
6.5. Key Trends

Chapter 7. Global Viral Inactivation market  Analysis and Forecasts, by Application
7.1. Key Findings
7.2. Introduction
7.3. Market size (US$ Mn) Forecast, by Application, 2017-2025
7.3.1. Blood and Blood Products
7.3.2. Vaccines
7.3.3. Cell and Tissue Culture 
7.4. Market Attractiveness, by Application

Chapter 8. Global Viral Inactivation market  Analysis and Forecasts, by End-user
8.1. Key Findings
8.2. Introduction
8.3. Market size (US$ Mn) Forecast by End-user, 2017-2025
8.3.1. Pharmaceutical and Biotechnology Companies
8.3.2. Blood banks and Hospitals
8.3.3. Contract Research Organizations
8.3.4. Others 
8.4. Market Attractiveness by End-user

Chapter 9. Global Viral Inactivation market  Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific 
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness, by Region

Chapter 10. North America Viral Inactivation market  Analysis and Forecast
10.1. Key Findings 
10.2. Market Overview
10.3. Market Value (US$ Mn) Forecast, by Country, 2017-2025
10.3.1. U.S.
10.3.2. Canada
10.4. Market size (US$ Mn) Forecast, by Method, 2017-2025
10.4.1. Chemical method
10.4.1.1. Solvent & Detergents
10.4.1.2. Alkylating Agents
10.4.1.3. pH Concentration
10.4.2. Radiation Method
10.4.3. Other Methods
10.5. Market size (US$ Mn) Forecast, by Application, 2017-2025
10.5.1. Blood and Blood Products
10.5.2. Vaccines
10.5.3. Cell and Tissue Culture 
10.6. Market size (US$ Mn) Forecast by End-user, 2017-2025
10.6.1. Pharmaceutical and Biotechnology Companies
10.6.2. Blood banks and Hospitals
10.6.3. Contract Research Organizations
10.6.4. Others 
10.7. Market Attractiveness Analysis 
10.7.1. By Country
10.7.2. By Method
10.7.3. By Application
10.7.4. By End-user
10.8. Key Trends

Chapter 11. Europe Viral Inactivation market  Analysis and Forecast
11.1. Key Findings 
11.2. Market Overview
11.3. Market size (US$ Mn) Forecast By Country, 2017-2025
11.3.1. Germany
11.3.2. U.K.
11.3.3. France
11.3.4. Spain
11.3.5. Italy
11.3.6. Rest of Europe
11.4. Market size (US$ Mn) Forecast, by Method, 2017-2025
11.4.1. Chemical method
11.4.1.1. Solvent & Detergents
11.4.1.2. Alkylating Agents
11.4.1.3. pH Concentration
11.4.2. Radiation Method
11.4.3. Other Methods
11.5. Market size (US$ Mn) Forecast, by Application, 2017-2025
11.5.1. Blood and Blood Products
11.5.2. Vaccines
11.5.3. Cell and Tissue Culture 
11.6. Market size (US$ Mn) Forecast by End-user, 2017-2025
11.6.1. Pharmaceutical and Biotechnology Companies
11.6.2. Blood banks and Hospitals
11.6.3. Contract Research Organizations
11.6.4. Others 
11.7. Market Attractiveness Analysis 
11.7.1. By Country
11.7.2. By Method
11.7.3. By Application
11.7.4. By End-user
11.8. Key Trends

Chapter 12. Asia Pacific Viral Inactivation market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market size (US$ Mn) Forecast, by Method, 2017-2025
12.4.1. Chemical method
12.4.1.1. Solvent & Detergents
12.4.1.2. Alkylating Agents
12.4.1.3. pH Concentration
12.4.2. Radiation Method
12.4.3. Other Methods
12.5. Market size (US$ Mn) Forecast, by Application, 2017-2025
12.5.1. Blood and Blood Products
12.5.2. Vaccines
12.5.3. Cell and Tissue Culture 
12.6. Market size (US$ Mn) Forecast by End-user, 2017-2025
12.6.1. Pharmaceutical and Biotechnology Companies
12.6.2. Blood banks and Hospitals
12.6.3. Contract Research Organizations
12.6.4. Others 
12.7. Market Attractiveness Analysis 
12.7.1. By Country
12.7.2. By Method
12.7.3. By Application
12.7.4. By End-user
12.8. Key Trends

Chapter 13. Latin America Viral Inactivation market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country, 2017-2025
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market size (US$ Mn) Forecast, by Method, 2017-2025
13.4.1. Chemical method
13.4.1.1. Solvent & Detergents
13.4.1.2. Alkylating Agents
13.4.1.3. pH Concentration
13.4.2. Radiation Method
13.4.3. Other Methods
13.5. Market size (US$ Mn) Forecast, by Application, 2017-2025
13.5.1. Blood and Blood Products
13.5.2. Vaccines
13.5.3. Cell and Tissue Culture 
13.6. Market size (US$ Mn) Forecast by End-user, 2017-2025
13.6.1. Pharmaceutical and Biotechnology Companies
13.6.2. Blood banks and Hospitals
13.6.3. Contract Research Organizations
13.6.4. Others 
13.7. Market Attractiveness Analysis 
13.7.1. By Country
13.7.2. By Method
13.7.3. By Application
13.7.4. By End-user
13.8. Key Trends

Chapter 14. Middle East and Africa Viral Inactivation market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4. Market size (US$ Mn) Forecast, by Method, 2017-2025
14.4.1. Chemical method
14.4.1.1. Solvent & Detergents
14.4.1.2. Alkylating Agents
14.4.1.3. pH Concentration
14.4.2. Radiation Method
14.4.3. Other Methods
14.5. Market size (US$ Mn) Forecast, by Application, 2017-2025
14.5.1. Blood and Blood Products
14.5.2. Vaccines
14.5.3. Cell and Tissue Culture 
14.6. Market size (US$ Mn) Forecast by End-user, 2017-2025
14.6.1. Pharmaceutical and Biotechnology Companies
14.6.2. Blood banks and Hospitals
14.6.3. Contract Research Organizations
14.6.4. Others 
14.7. Market Attractiveness Analysis 
14.7.1. By Country
14.7.2. By Method
14.7.3. By Application
14.7.4. By End-user
14.8. Key Trends

Chapter 15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.2.1. Parker Hannifin Corporation
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Strategic Overview
15.2.2. Merck & Co., Inc.  
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. Shandong Weigao Group Medical Polymer Company Limited
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Financial Overview
15.2.3.5. Strategic Overview
15.2.4. Sartorius AG
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Financial Overview
15.2.4.5. Strategic Overview
15.2.5. Cerus Corporation
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Financial Overview
15.2.5.5. Strategic Overview
15.2.6. Macopharma SA 
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Financial Overview
15.2.6.5. Strategic Overview
15.2.7. Terumo BCT, Inc. 
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Financial Overview
15.2.7.5. Strategic Overview
15.2.8. Thermo Fisher Scientific Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Financial Overview
15.2.8.5. Strategic Overview
15.2.9. V.I.P.S. SA
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Financial Overview
15.2.9.5. Strategic Overview

List of Table

Table 01: Global Viral Inactivation Market Size (US$ Mn) Forecast, by Method, 2015–2025
Table 02: Global Viral Inactivation Market Size (US$ Mn) Forecast, Chemical Method, 2015–2025
Table 03: Global Viral Inactivation Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 04: Global Viral Inactivation Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 05: Global Viral Inactivation Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 06: North America Viral Inactivation Market Size (US$ Mn) Forecast, by Country/ Sub-region, 2015–2025
Table 07: North America Viral Inactivation Market Size (US$ Mn) Forecast, by Method, 2015–2025
Table 08: North America Viral Inactivation Market Size (US$ Mn) Forecast, by Chemical method, 2015–2025
Table 09: North America Viral Inactivation Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 10: North America Viral Inactivation Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 11: Europe Viral Inactivation Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
Table 12: Europe Viral Inactivation Market Value (US$ Mn) Forecast, by Method, 2015–2025
Table 13: Europe Viral Inactivation Market Size (US$ Mn) Forecast, by Chemical Method, 2015–2025
Table 14: Europe Viral Inactivation Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 15: Europe Viral Inactivation Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 16: Asia Pacific Viral Inactivation Market Value (US$ Mn) Forecast, by Country/ Sub-region, 2015–2025
Table 17: Asia Pacific Viral Inactivation Market Value (US$ Mn) Forecast, by Method, 2015–2025
Table 18: Asia Pacific Viral Inactivation Market Size (US$ Mn) Forecast, by Chemical Method, 2015–2025
Table 19: Asia Pacific Viral Inactivation Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 20: Asia Pacific Viral Inactivation Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 21: Latin America Viral Inactivation Market Size (US$ Mn) Forecast, by Country/ Sub-region, 2015–2025
Table 22: Latin America Viral Inactivation Market Size (US$ Mn) Forecast, by Method, 2015–2025
Table 23: Latin America Viral Inactivation Market Size (US$ Mn) Forecast, by Chemical Method, 2015–2025
Table 24: Latin America Viral Inactivation Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 25: Latin America Viral Inactivation Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 26: Middle East & Africa Viral Inactivation Market Size (US$ Mn) Forecast, by Country/ Sub-region, 2015–2025
Table 27: Middle East & Africa Viral Inactivation Market Size (US$ Mn) Forecast, by Method, 2015–2025
Table 28: Middle East & Africa Viral Inactivation Market Size (US$ Mn) Forecast, by Chemical Method, 2015–2025
Table 29: Middle East & Africa Viral Inactivation Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 30: Middle East & Africa Viral Inactivation Market Size (US$ Mn) Forecast, by End-user, 2015–2025

List of Chart

Figure 01: Global Viral Inactivation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2025
Figure 02: Global Viral Inactivation Market Value Share, by Method (2016)
Figure 03: Global Viral Inactivation Market Value Share, by Application (2016)
Figure 04: Global Viral Inactivation Market Value Share, by End-user (2016)
Figure 05: Global Viral Inactivation Market Value Share, by Region (2016)
Figure 06: Global Viral Inactivation Market Value Share Analysis, by Method, 2016 and 2025
Figure 07: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical Method, 2016–2025
Figure 08: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Method, 2016–2025
Figure 09: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Other Methods, 2016–2025
Figure 10: Global Viral Inactivation Market Attractiveness Analysis, by Method, 2017–2025
Figure 11: Global Viral Inactivation Market Value Share Analysis, by Application, 2016 and 2025
Figure 12: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood and Blood Products, 2017–2025
Figure 13: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vaccines, 2017–2025
Figure 14: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cell & Tissue Culture, 2017–2025
Figure 15: Global Viral Inactivation Market Attractiveness Analysis, by Application, 2017–2025
Figure 16: Global Viral Inactivation Market Value Share Analysis, by End-user, 2016 and 2025
Figure 17: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmaceutical and Biotechnology companies, 2016–2025
Figure 18: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Banks and Hospitals, 2016–2025
Figure 19: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Contract Research Organizations, 2016–2025
Figure 20: Global Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2025
Figure 21: Global Viral Inactivation Market Attractiveness
Figure 22: Global Viral Inactivation Market Value Share Analysis, by Region, 2016 and 2025
Figure 23: Global Viral Inactivation Market Attractiveness Analysis, by Region, 2017–2025
Figure 24: North America Viral Inactivation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2025
Figure 25: North America Viral Inactivation Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 26: North America Viral Inactivation Market Value Share Analysis, by Country/ Sub-region, 2016 and 2025
Figure 27: North America Viral Inactivation Market Value Share Analysis, by Method, 2016 and 2025
Figure 28: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical method, 2016–2025
Figure 29: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation method,     2016–2025
Figure 30: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Other Methods, 2016–2025
Figure 31: North America Viral Inactivation Market Value Share Analysis, by Application, 2016 and 2025
Figure 32: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood and Blood Products, 2016–2025
Figure 33: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vaccines, 2016–2025
Figure 34: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cell & Tissue Culture, 2016–2025
Figure 35: North America Viral Inactivation Market Value Share Analysis, by End-user, 2016 and 2025
Figure 36: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmaceutical and Biotechnology Companies, 2016–2025
Figure 37: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Banks and Hospitals, 2016–2025
Figure 38: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Contract Research Organizations, 2016–2025
Figure 39: North America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2025
Figure 40: North America Viral Inactivation Market Attractiveness Analysis, by Method, 2017–2025
Figure 41: North America Viral Inactivation Market Attractiveness Analysis, by Application, 2017–2025
Figure 42: North America Viral Inactivation Market Attractiveness Analysis, by End-user, 2017-2025
Figure 43: Europe Viral Inactivation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2025
Figure 44: Europe Viral Inactivation Market Attractiveness Analysis, by Country / Sub-region, 2017–2025
Figure 45: Europe Viral Inactivation Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
Figure 46: Europe Viral Inactivation Market Value Share Analysis, by Method, 2016 and 2025
Figure 47: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical, 2016–2025
Figure 48: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Method, 2016–2025
Figure 49: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Other Methods, 2016–2025
Figure 50: Europe Viral Inactivation Market Value Share Analysis (US$ Mn), by Application, 2016 and 2025
Figure 51: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood & Blood Products, 2016–2025
Figure 52: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vaccines, 2016–2025
Figure 53: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cell & Tissue Culture, 2016–2025
Figure 54: Europe Viral Inactivation Market Value share Analysis, by End-user, 2016 and 2025
Figure 55: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmaceutical & Biotechnology Companies, 2016–2025
Figure 56: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Banks & Hospitals, 2016–2025
Figure 57: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Contract Research Organization, 2016–2025
Figure 58: Europe Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2025
Figure 59: Europe Viral Inactivation Market Attractiveness Analysis, by Method, 2017–2025
Figure 60: Europe Viral Inactivation Market Attractiveness Analysis, by Application, 2017–2025
Figure 61: Europe Viral Inactivation Market Attractiveness Analysis, by End-user, 2017–2025
Figure 62: Asia Pacific Viral Inactivation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2025
Figure 63: Asia Pacific Viral Inactivation Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 64: Asia Pacific Viral Inactivation Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 65: Asia Pacific Viral Inactivation Market Value Share Analysis, by Method, 2016 and 2025
Figure 66: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical Method, 2016–2025
Figure 67: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Method, 2016–2025
Figure 68: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Other Methods, 2016–2025
Figure 69: Asia Pacific Viral Inactivation Market Value Share Analysis, by Application, 2016 and 2025
Figure 70: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood & Blood Products, 2016–2025
Figure 71: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vaccines, 2016–2025
Figure 72: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cell & Tissue Culture, 2016–2025
Figure 73: Asia Pacific Viral Inactivation Market Value share Analysis, by End-user, 2016 and 2025
Figure 74: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmaceutical & Biotechnology Companies, 2016–2025
Figure 75: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Banks & Hospitals, 2016–2025
Figure 76: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Contract Research Organizations, 2016–2025
Figure 77: Asia Pacific Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2025
Figure 78: Asia Pacific Viral Inactivation Market Attractiveness Analysis, by Method, 2017–2025
Figure 79: Asia Pacific Viral Inactivation Market Attractiveness Analysis, by Application, 2017–2025
Figure 80: Asia Pacific Viral Inactivation Market Attractiveness Analysis, by End-user, 2017–2025
Figure 81: Latin America Viral Inactivation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2025
Figure 82: Latin America Viral Inactivation Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
Figure 83: Latin America Viral Inactivation Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 84: Latin America Viral Inactivation Market Value Share Analysis, by Method, 2016 and 2025
Figure 85: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical Method, 2016–2025
Figure 86: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation method, 2016–2025
Figure 87: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by other methods 2016–2025
Figure 88: Latin America Viral Inactivation Market Value Share Analysis, by Application, 2016 and 2025
Figure 89: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood and Blood Products 2016–2025
Figure 90: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vaccines, 2016–2025
Figure 91: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cell and Tissue Culture, 2016–2025
Figure 92: Latin America Viral Inactivation Market Value Share Analysis, by End-user, 2016 and 2025
Figure 93: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmaceutical and Biotechnology companies, 2016–2025
Figure 94: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Banks and Hospitals, 2016–2025
Figure 95: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Contract Research Organizations 2016–2025
Figure 96: Latin America Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2025
Figure 97: Latin America Viral Inactivation Market Attractiveness Analysis, by Method, 2017–2025
Figure 98: Latin America Viral Inactivation Market Attractiveness Analysis, by Application, 2017–2025
Figure 99: Latin America Viral Inactivation Market Attractiveness Analysis, by End-user, 2017-2025
Figure 100: Middle East & Africa Viral Inactivation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2025
Figure 101: Middle East & Africa Viral Inactivation Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
Figure 102: Middle East & Africa Viral Inactivation Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 103: Middle East & Africa Viral Inactivation Market Value Share Analysis, by Method, 2016 and 2025
Figure 104: Middle East & Africa Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemical Method, 2016–2025
Figure 105: Middle East & Africa Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation method, 2016–2025
Figure 106: Middle East & Africa Viral Inactivation Market Revenue (US$ Mn) and Y-o-Y Growth (%), by other methods, 2016–2025
Figure 107: Middle East & Africa Viral Inactivation Market Value Share Analysis, by Application, 2016 and 2025
Figure 108: Middle East & Africa Blood and Blood Products Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2025
Figure 109: Middle East & Africa Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2025
Figure 110: Middle East & Africa Cell Culture Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2025
Figure 111: Middle East & Africa Viral Inactivation Market Value Share Analysis, by End-user, 2016 and 2025
Figure 112: Middle East & Africa Pharmaceutical and Biotechnology companies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2025
Figure 113: Middle East & Africa Blood Banks and Hospitals Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2025
Figure 114: Middle East & Africa Contract Research Organizations Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2025
Figure 115: Middle East & Africa Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2025
Figure 116: Middle East & Africa Viral Inactivation Market Attractiveness Analysis, by Method, 2017–2025
Figure 117: Middle East & Africa Viral Inactivation Market Attractiveness Analysis, by Application, 2017–2025
Figure 118: Middle East & Africa Viral Inactivation Market Attractiveness Analysis, by End-user, 2017–2025

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *